Safety and Tolerability of AC01 in patients with heart failure

2022-500347-20-00 Protocol AC01-01 Phase I and Phase II (Integrated) - Other Ended

Start 23 Feb 2023 · End 20 Oct 2025 · Status Ended · 3 EU/EEA countries · 10 sites · Protocol AC01-01

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 62
Countries 3
Sites 10

Heart Failure

Key facts

Sponsor
Anacardio AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
23 Feb 2023 → 20 Oct 2025
Decision date (initial)
2022-11-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-500347-20-00
WHO UTN
U1111-1276-9209

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Heart Failure

VersionLevelCodeTermSystem organ class
20.0 LLT 10078289 Heart failure with reduced ejection fraction 10007541

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Anacardio AB

Sponsor organisation
Anacardio AB
Address
Nanna Svartz Vag 4
City
Solna
Postcode
171 65
Country
Sweden

Scientific contact point

Organisation
Anacardio AB
Contact name
Patrik Stromberg

Public contact point

Organisation
Anacardio AB
Contact name
Goran Westerberg

Locations

3 EU/EEA countries · 10 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 8 2
Netherlands Ended 17 5
Sweden Ended 21 3
Rest of world
United Kingdom
16

Investigational sites

Italy

2 sites · Ended
University Of Brescia
Cardiology, Piazzale Spedali Civili 1, 25123, Brescia
Azienda Sanitaria Universitaria Giuliano Isontina
Cardiology, Via Costantino Costantinides 2, 34128, Trieste

Netherlands

5 sites · Ended
Erasmus MC
Cardiology, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Universitair Medisch Centrum Utrecht
Cardiology, Heidelberglaan 100, 3584 CX, Utrecht
Amsterdam UMC
Cardiology, De Boelelaan 1117, 1081 HV, Amsterdam
Pharmaceutical Research Associates Group B.V.
Clinical Research Unit Groningen, Van Swietenlaan 6, 9728 NZ, Groningen
University Hospital Maastricht
Cardiology, P. O. Box 5800, 6202 AZ, Maastricht

Sweden

3 sites · Ended
Region Skane - Skanes Universitetssjukhus
Cardiology, Entregatan 7, Lunds Allhelgonafors, Lund
Karolinska University Hospital
Cardiology, Eugeniavagen 3, 171 64, Solna
Sahlgrenska University Hospital - Vastra Goetalandsregionen
Cardiology, Bla Straket 5, 413 46, Goteborg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2025-03-17 2025-09-16 2025-05-14 2025-09-10
Netherlands 2023-08-28 2025-10-13 2023-08-28 2025-09-10
Sweden 2023-02-23 2025-10-07 2023-02-23 2025-09-10

Application history

16 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-05-06 Netherlands Acceptable with conditions
2022-08-22
2022-10-28
2 SUBSTANTIAL MODIFICATION SM-1 2022-12-09 Acceptable with conditions 2023-02-07
3 NON SUBSTANTIAL MODIFICATION NSM-2 2023-02-22 Acceptable with conditions 2023-02-22
4 NON SUBSTANTIAL MODIFICATION NSM-3 2023-03-02 Netherlands Acceptable with conditions 2023-03-02
5 SUBSTANTIAL MODIFICATION SM-2 2023-06-16 Netherlands Acceptable
2023-08-07
2023-08-07
6 NON SUBSTANTIAL MODIFICATION NSM-4 2023-08-07 Netherlands 2023-08-07
7 SUBSTANTIAL MODIFICATION SM-3 2023-08-23 Acceptable 2023-09-27
8 NON SUBSTANTIAL MODIFICATION NSM-5 2024-01-03 Netherlands Acceptable 2024-01-03
9 SUBSTANTIAL MODIFICATION SM-4 2024-01-04 Acceptable 2024-02-15
10 SUBSTANTIAL MODIFICATION SM-5 2024-01-04 Netherlands Acceptable 2024-02-16
11 NON SUBSTANTIAL MODIFICATION NSM-6 2024-03-18 Acceptable 2024-03-18
12 NON SUBSTANTIAL MODIFICATION NSM-7 2024-03-27 Acceptable
13 SUBSTANTIAL MODIFICATION SM-6 2024-05-08 Netherlands Acceptable
2024-06-24
2024-06-24
14 SUBSTANTIAL MODIFICATION SM-7 2024-10-22 Netherlands Acceptable
2025-02-06
2025-02-10
15 SUBSTANTIAL MODIFICATION SM-8 2025-02-14 Acceptable 2025-03-25
16 NON SUBSTANTIAL MODIFICATION NSM-8 2025-03-27 Netherlands Acceptable 2025-03-27